human egf Search Results


number: 1150-04-100  (Gold Biotechnology Inc)
94
Gold Biotechnology Inc number: 1150-04-100
Number: 1150 04 100, supplied by Gold Biotechnology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/number: 1150-04-100/product/Gold Biotechnology Inc
Average 94 stars, based on 1 article reviews
number: 1150-04-100 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
stimulation by heregulin  (R&D Systems)
94
R&D Systems stimulation by heregulin
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Stimulation By Heregulin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stimulation by heregulin/product/R&D Systems
Average 94 stars, based on 1 article reviews
stimulation by heregulin - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant human egf  (R&D Systems)
92
R&D Systems recombinant human egf
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Recombinant Human Egf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human egf/product/R&D Systems
Average 92 stars, based on 1 article reviews
recombinant human egf - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
anti human hb egf neutralising antibodies  (R&D Systems)
90
R&D Systems anti human hb egf neutralising antibodies
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Anti Human Hb Egf Neutralising Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human hb egf neutralising antibodies/product/R&D Systems
Average 90 stars, based on 1 article reviews
anti human hb egf neutralising antibodies - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
egf  (R&D Systems)
96
R&D Systems egf
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Egf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egf/product/R&D Systems
Average 96 stars, based on 1 article reviews
egf - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
human egf  (Miltenyi Biotec)
95
Miltenyi Biotec human egf
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Human Egf, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human egf/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
human egf - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
human epithelial growth factor egf  (Miltenyi Biotec)
95
Miltenyi Biotec human epithelial growth factor egf
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Human Epithelial Growth Factor Egf, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human epithelial growth factor egf/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
human epithelial growth factor egf - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
human hb-egf(dtr)( af-259-na  (R&D Systems)
95
R&D Systems human hb-egf(dtr)( af-259-na
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Human Hb Egf(Dtr)( Af 259 Na, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hb-egf(dtr)( af-259-na/product/R&D Systems
Average 95 stars, based on 1 article reviews
human hb-egf(dtr)( af-259-na - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
growth factor  (R&D Systems)
93
R&D Systems growth factor
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/growth factor/product/R&D Systems
Average 93 stars, based on 1 article reviews
growth factor - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
recombinant human hb egf  (R&D Systems)
90
R&D Systems recombinant human hb egf
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Recombinant Human Hb Egf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human hb egf/product/R&D Systems
Average 90 stars, based on 1 article reviews
recombinant human hb egf - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human recombinant egf  (R&D Systems)
99
R&D Systems human recombinant egf
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Human Recombinant Egf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant egf/product/R&D Systems
Average 99 stars, based on 1 article reviews
human recombinant egf - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
human hb egf protein  (R&D Systems)
93
R&D Systems human hb egf protein
Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for <t>heregulin-β</t> (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.
Human Hb Egf Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hb egf protein/product/R&D Systems
Average 93 stars, based on 1 article reviews
human hb egf protein - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for heregulin-β (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.

Journal: Cellular signalling

Article Title: Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

doi: 10.1016/j.cellsig.2011.09.030

Figure Lengend Snippet: Fig. 2. Dose response and sensitivity properties of the PI3K/PTEN/AKT signalling network. (A) pHER2 dose dependence for heregulin-β (HRG) concentration (solid line), pAKT dose dependence for HRG in the absence (dashed line) and presence of PTEN inhibitor, 50 nM bpV(pic) (dotted line). (B) pHER2 and pAKT dose dependencies for pertuzumab (solid and dashed lines, respectively) at 95 nM and 1 μM of HER2 concentration (thick and thin lines, respectively). Dotted line — pAKT dose dependence at three-fold increase in activity of CK2/GSK3β reaction of PTEN phosphorylation. Points on thick lines — experimental data (see Fig. 3 in [33]). (C) pHER2 and pAKT dose dependencies for HER2 concentration in the absence (thick solid and dashed lines, respectively) and presence of 100 nM pertuzumab (thin solid and dashed lines, respectively). (D) The dependence of sensitivities of the whole signalling network, SSN (solid line), receptor subsystem SRSS (dotted line), and signalling transaction subsystem SSTS (dashed line) on pertuzumab concentration. (E) Western blot analysis of the dose dependence of pHER2 (left) and pAKT (right) to HRG concentration (0 nM (control), 0.01 nM, 0.1 nM, 1 nM and 10 nM) at 5 and 30 min.

Article Snippet: Cells were treatedwith UCN-01 (protein kinase inhibitor; Calbiochem#539644; final concentration of 1 μM), LY294002 (PI3 kinase inhibitor; Calbiochem#440204; final concentration 20 μM), pertuzumab (HER2 inhibitor; final concentration 100 nM) and stimulation by heregulin (R&D Systems; 396-HB-CF) was at final concentration of 1 nM.

Techniques: Concentration Assay, Activity Assay, Phospho-proteomics, Western Blot, Control

Fig. 6. (A) Western blot analysis of the inhibition effect on pAKT of varying concentrations of PTEN inhibitor, bpV(pic) (5 nM, 10 nM, 25 nM, 50 nM, 100 nM) at 1 nM heregulin, HRG in PE04 cells. (B) Theoretical pAKT dose dependence on PTEN concentration at saturated HRG signal (thin line) and at HER2 inhibition by pertuzumab (thick line). Squares — ex- perimental data on the dependence of pAKT concentration on PTEN expression level in 13 ovarian cancer lines (in relative units). Circles — experimental data on the dependence of pAKT concentration on PTEN expression for basal-like breast carcinoma (in relative units) [28]. (C) Experimental data (mean±S.D., n=3) on the effects of combinations of PDK1 in- hibition by 7.5 μM UCN-01, HER2 inhibition by 100 nM pertuzumab (2C4) and PTEN inhi- bition by 50 μM bpV(pic).

Journal: Cellular signalling

Article Title: Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

doi: 10.1016/j.cellsig.2011.09.030

Figure Lengend Snippet: Fig. 6. (A) Western blot analysis of the inhibition effect on pAKT of varying concentrations of PTEN inhibitor, bpV(pic) (5 nM, 10 nM, 25 nM, 50 nM, 100 nM) at 1 nM heregulin, HRG in PE04 cells. (B) Theoretical pAKT dose dependence on PTEN concentration at saturated HRG signal (thin line) and at HER2 inhibition by pertuzumab (thick line). Squares — ex- perimental data on the dependence of pAKT concentration on PTEN expression level in 13 ovarian cancer lines (in relative units). Circles — experimental data on the dependence of pAKT concentration on PTEN expression for basal-like breast carcinoma (in relative units) [28]. (C) Experimental data (mean±S.D., n=3) on the effects of combinations of PDK1 in- hibition by 7.5 μM UCN-01, HER2 inhibition by 100 nM pertuzumab (2C4) and PTEN inhi- bition by 50 μM bpV(pic).

Article Snippet: Cells were treatedwith UCN-01 (protein kinase inhibitor; Calbiochem#539644; final concentration of 1 μM), LY294002 (PI3 kinase inhibitor; Calbiochem#440204; final concentration 20 μM), pertuzumab (HER2 inhibitor; final concentration 100 nM) and stimulation by heregulin (R&D Systems; 396-HB-CF) was at final concentration of 1 nM.

Techniques: Western Blot, Inhibition, Concentration Assay, Expressing